HemoClear BV

HemoClear BV is a manufacturing and medical devices company founded in 2015 with the aim to provide platelet-rich red blood cells for autologous blood transfusion. The innovative design of the HemoClear blood filter allows for the recovery of red blood cells from patients' shed blood during severe blood loss. Utilizing cross-flow filtration by gravity, the sterile HemoClear device demonstrates a high degree of specificity for erythrocytes, separating them from other fluids and plasma. The filtered erythrocytes then undergo re-infusion, while the plasma fluid containing toxins and pathological elements is destructed as waste. Autologous blood transfusion, derived from the same individual, is gaining widespread acceptance as the preferred choice whenever possible. This method presents various advantages such as reduced risk of transmission of infection, transfusion reactions, and immunosuppression. It also eliminates the need for extensive compatibility testing and reduces the demand on allogeneic blood supplies. Furthermore, it may be acceptable to some Jehovah's Witness patients. HemoClear BV's technology and focus on improving the efficiency and safety of blood transfusions present significant potential in the medical field. However, it's essential for the company to attract substantial investment to scale their operations and enhance market penetration. With the right investors and tailored strategic partnerships, HemoClear BV could revolutionize the landscape of blood transfusion technology and make a substantial impact in the medical industry.